CNS Pharmaceuticals, Inc. (CNSP) is a publicly traded company in the Unknown sector. Across all available filings, 6 corporate insiders have executed 38 transactions totaling $591.7K, demonstrating a bullish sentiment with $325.5K in net insider flow. The most recent transaction on Feb 1, 2024 involved a purchase of 166,666 shares valued at $50.0K.
No significant insider buying has been recorded for CNSP in the recent period.
No significant insider selling has been recorded for CNSP in the recent period.
Based on recent SEC filings, insider sentiment for CNSP is bullish with an Insider Alignment Score of 78/100 and a net flow of $325.5K. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at CNS Pharmaceuticals, Inc. (CNSP) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 6 insiders are actively trading CNSP stock, having executed 38 transactions in the past 90 days. The most active insider is Christopher Downs (Executive), who has made 8 transactions totaling $374.0K.
Get notified when executives and directors at CNSP file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 1, 2024 | M. Climaco John | Executive | Purchase | 166,666 | $0.30 | $50.0K | |
| Feb 1, 2024 | Downs Christopher | Executive | Purchase | 66,666 | $0.30 | $20.0K | |
| Feb 1, 2024 | Anthony Evans Carl | Executive | Purchase | 33,333 | $0.30 | $10.0K | |
| Feb 1, 2024 | Gumulka Jerzy | Executive | Purchase | 33,333 | $0.30 | $10.0K | |
| Aug 22, 2023 | Downs Christopher | Executive | Purchase | 27,000 | $1.27 | $34.3K | |
| Aug 16, 2023 | M. Climaco John | Executive | Purchase | 2,750 | $1.80 | $5.0K | |
| Apr 28, 2023 | Downs Christopher | Executive | Option Exercise | 521 | $N/A | $0 | |
| Apr 28, 2023 | M. Climaco John | Executive | Option Exercise | 1,250 | $N/A | $0 | |
| Apr 19, 2023 | Gumulka Jerzy | Executive | Purchase | 2,500 | $1.70 | $4.3K | |
| Apr 17, 2023 | Downs Christopher | Executive | Purchase | 3,100 | $3.20 | $9.9K | |
| Apr 12, 2023 | M. Climaco John | Executive | Purchase | 15,000 | $0.69 | $10.3K | |
| Apr 10, 2023 | Gumulka Jerzy | Executive | Purchase | 7,173 | $0.74 | $5.3K | |
| Mar 28, 2023 | Priebe Waldemar | Executive | Sale | 10,000 | $1.04 | $10.4K | 10b5-1 |
| Mar 27, 2023 | Priebe Waldemar | Executive | Sale | 5,000 | $1.09 | $5.5K | 10b5-1 |
| Mar 24, 2023 | Priebe Waldemar | Executive | Sale | 5,000 | $1.08 | $5.4K | 10b5-1 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 13 | $458.6K | 73.7% |
Sale(S) | 17 | $133.1K | 21.4% |
Award(A) | 5 | $30.8K | 4.9% |
Exercise(M) | 2 | $0 | 0.0% |
Other(J) | 1 | $0 | 0.0% |
Insiders at CNS Pharmaceuticals, Inc. are accumulating shares at an accelerated pace. With 6 insiders making 38 transactions totaling $458.6K in purchases versus $133.1K in sales, the net buying activity of $325.5K signals strong executive confidence. Christopher Downs (Executive) leads the buying activity with $374.0K in transactions across all time.